Unlocking the Value of Biosimilars: Challenges and Solutions
By Staff Writer
August 10, 2023
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has recently published a report highlighting the gaps and challenges in the value assessment of biosimilars.
The report brings to light the ongoing debate on how to accurately assess the value of biosimilars, especially when they request reimbursement for the same indication as the reference biologic. The report also touches upon the different regulatory requirements for biosimilars across various jurisdictions.
The aim of this review is to provide an overview of the existing challenges and propose potential approaches to address them. This could pave the way for improved methodologies in economic evaluation and better access to these therapies in different jurisdictions.
Assessing the value of a biosimilar, a biological product highly similar to an already approved biological product, can be done through either a price comparison or a full economic evaluation. The choice of method depends on factors such as the relative efficacy of the reference biologic and the biosimilar, indication extrapolation, and value assessment in biologic-naive and biologic-experienced patients. A price comparison is typically used when the two products differ significantly in terms of costs, but not effectiveness. However, a full economic evaluation is required when the reference biologic is not reimbursed, has not been appraised, or is not the standard of care. Some countries, such as Belgium, France, and the Netherlands, classify biosimilars as products with no added therapeutic value compared to the reference biologic. Therefore, they have implemented an abbreviated pricing and reimbursement pathway for biosimilars. The value assessment of a biosimilar is a dynamic process and may need to be revisited as new evidence emerges.
The ISPOR Special Interest Group on Biosimilars is committed to generating new insights in this field by interviewing experts at Health Technology Assessment (HTA) agencies worldwide.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.